Parkinson's disease: diagnosis, treatment and GP coordination in Australia

Parkinson’s disease — what GPs need to know

Parkinson’s disease is the second most common neurodegenerative condition in Australia after Alzheimer’s disease, affecting approximately 80,000 Australians with rising prevalence as the population ages. Parkinson’s Australia reports mean age at onset of 60–65 years, though 5–10% of cases are young-onset (under 50), with a male-to-female ratio of roughly 1.5:1.

The underlying biology is loss of dopaminergic neurons in the substantia nigra pars compacta, with accumulation of misfolded alpha-synuclein in structures called Lewy bodies. Symptoms typically emerge after approximately 50–70% of nigral dopaminergic neurons are lost — by which point disease has usually been progressing for many years. The Braak staging model explains why non-motor features involving the gut, olfactory bulb, and brainstem often appear a decade or more before motor problems begin.

As Bloem et al. (Lancet 2021) describe, Parkinson’s disease is a multisystem disorder encompassing autonomic dysfunction, sleep disturbance, cognitive change, and mood — not simply a movement disorder. The GP’s role spans initial recognition, coordination of multidisciplinary care, management of non-motor and late-stage features, and communication with the person and their family at every stage of the disease trajectory.

A. Core clinical — the AU general-practice framework

Diagnostic criteria

The Movement Disorder Society 2015 criteria require bradykinesia (mandatory) plus at least one of: rigidity (lead-pipe, with cogwheel superimposed when tremor is present), rest tremor (4–6 Hz, classically pill-rolling, asymmetric, decreases with action), or postural instability (a late feature — if early, consider atypical parkinsonism).

Supportive criteria include a dramatic and sustained levodopa response, levodopa-induced dyskinesia, rest tremor of a limb, and cardiac sympathetic denervation on MIBG imaging. Absolute exclusions ruling out Parkinson’s disease include cerebellar abnormalities, downward vertical supranuclear gaze palsy, the absence of any response to high-dose levodopa, and a normal functional imaging of presynaptic dopaminergic systems.

Distinguishing common mimics — the tremor differential

Tremor is the presenting symptom that brings many people to general practice. eTG Neurology and AMH both describe the key discriminators:

Feature	Parkinson’s	Essential tremor	Drug-induced	Physiological
State	Rest; decreases with action	Postural and action	Often postural	Postural
Rate	4–6 Hz	6–12 Hz	Variable	8–12 Hz
Symmetry	Typically asymmetric	Often bilateral	Bilateral	Bilateral
Family history	~10%	50–70%	—	—
Alcohol response	No	Yes (transient)	—	Variable
Treatment	Levodopa, dopamine agonist	Propranolol, primidone	Cease offender	Reassure, reduce caffeine

Drugs causing parkinsonism or tremor include dopamine receptor blockers (antipsychotics — haloperidol, risperidone, olanzapine; metoclopramide, prochlorperazine), sodium valproate, amiodarone, lithium, and SSRIs (subtle). Always review the medication list before attributing tremor to Parkinson’s disease.

Red flags for atypical parkinsonism warrant expedited specialist referral:

• PSP — early falls within 3 years of onset, vertical supranuclear gaze palsy
• MSA — early autonomic failure (orthostatic hypotension, urinary incontinence), cerebellar signs, inspiratory stridor
• CBD — asymmetric apraxia, alien limb phenomenon, cortical sensory loss
• DLB — early visual hallucinations, fluctuating cognition, severe neuroleptic sensitivity

Non-motor features — earlier than the tremor

Schapira et al. (Nat Rev Neurosci 2017) detail features that often precede motor onset by years and are underrecognised in general practice:

• Prodromal: hyposmia (>90%), constipation (often decades before motor onset), REM sleep behaviour disorder (strongest marker — Postuma 2019 found 80% phenoconvert to Parkinson’s, DLB, or MSA within 14 years)
• Neuropsychiatric: depression (30–50%), anxiety (40%), apathy, hallucinations, later psychosis
• Autonomic: orthostatic hypotension, urinary urgency and frequency, constipation, erectile dysfunction, drooling, sweating dysfunction
• Cognitive: subtle executive dysfunction early, progressing to mild cognitive impairment and Parkinson’s disease dementia (~80% prevalence at 20 years)
• Sleep: insomnia, restless legs, excessive daytime sleepiness, REM sleep behaviour disorder

Workup

• Levodopa trial — dramatic clinical response supports the diagnosis and is therapeutic simultaneously
• MRI brain — excludes vascular parkinsonism, normal pressure hydrocephalus, structural causes; “hummingbird sign” in PSP, “hot cross bun” in MSA
• DAT-SPECT — distinguishes neurodegenerative parkinsonism from essential tremor or drug-induced parkinsonism; Medicare-rebatable in selected specialist-requested indications at major Australian centres
• Olfactory testing — supportive in early disease
• Genetic testing — young-onset, family history; GBA, LRRK2, PRKN variants have emerging therapeutic relevance

B. Pharmacotherapy evidence

Levodopa — the cornerstone of treatment

Per eTG Neurology and AMH, levodopa/carbidopa (co-careldopa, Sinemet) and levodopa/benserazide (Madopar) remain the most effective symptomatic therapies. The LEAP trial (Verschuur NEJM 2019) — 445 participants, early versus delayed initiation over 80 weeks — demonstrated no disease-modifying benefit and no harm from earlier initiation. The clinical implication: start levodopa when symptoms affect daily function, without delay.

Long-term motor complications (wearing-off, peak-dose dyskinesia) develop in 30–50% of people after approximately 5 years of therapy. Management includes shortening dosing intervals, adding COMT inhibitors (entacapone, opicapone) to extend levodopa half-life, MAO-B inhibitors (rasagiline, selegiline, safinamide) to reduce wearing-off, or amantadine for dyskinesia. Large neutral amino acids from protein-rich meals compete with levodopa for intestinal absorption; eTG recommends taking levodopa 30 minutes before or 1 hour after protein-containing meals.

Dopamine agonists and impulse control disorders

Pramipexole, ropinirole, and rotigotine transdermal patch are used as monotherapy in younger patients (to delay levodopa-related dyskinesia over decades) or as adjuncts in established disease. Voon et al. (Lancet Neurology 2009) documented impulse control disorders in approximately 17% of people on dopamine agonists — pathological gambling, hypersexuality, compulsive shopping, binge eating, and punding. These behaviours are driven by dopaminergic stimulation of reward pathways, are socially devastating, and are frequently hidden from clinicians. The GP and specialist should ask directly at every review and inform the person’s partner or family. Management requires reducing or ceasing the dopamine agonist.

Other dopamine agonist effects requiring counselling: somnolence and sudden sleep attacks (significant driving risk), peripheral oedema, hallucinations. Avoid in people with cognitive impairment.

MAO-B inhibitors and advanced therapies

MAO-B inhibitors (rasagiline, selegiline, safinamide) provide modest symptomatic benefit and are useful as early monotherapy in mild disease or as adjuncts to reduce wearing-off. Despite early trials (DATATOP, ADAGIO) suggesting a disease-modifying signal, subsequent meta-analyses have not confirmed this — the current position per NICE NG71 and eTG is symptomatic effect only.

Advanced therapies, all specialist-initiated, include deep brain stimulation of STN or GPi for motor fluctuations in cognitively intact patients with good levodopa response, levodopa-carbidopa intestinal gel (Duodopa, Section 100) for continuous jejunal infusion in advanced fluctuations, and subcutaneous apomorphine for severe off-period management.

C. Non-pharmacological care and exercise

Exercise is the highest-evidence non-pharmacological intervention across all stages of Parkinson’s disease. Multiple RCTs support aerobic exercise, resistance training, tai chi (Li et al. NEJM 2012 showed significant falls reduction), and dance-based therapy for motor scores, balance, and quality of life. Parkinson’s Australia funds and coordinates PD Warrior (functional movement training) and connects patients with LSVT BIG (physiotherapy targeting movement amplitude) and LSVT LOUD (speech therapy targeting voice volume and swallowing) practitioners nationally.

Recommended exercise approaches:

• Aerobic exercise 150 minutes/week at moderate-to-vigorous intensity — improves gait speed, motor scores, and possibly promotes neuroprotective BDNF signalling
• Resistance training — improves strength and balance
• Tai chi and dance therapy (tango, ballroom) — balance, cueing, social engagement
• Boxing-based programs (Rock Steady type) — combining aerobic, balance, and cognitive elements

What lacks evidence or causes harm: Coenzyme Q10 failed the NET-PD QE3 phase III trial; creatine failed the LS-1 trial. Stem-cell injections offered by private clinics are not evidence-based and carry safety risks. Coffee enemas and detox protocols have no evidence. Cannabis-based products may help some symptoms (sleep, pain) but evidence is insufficient for routine use and cognitive adverse effects are a concern.

Mindfulness and CBT have RCT support for reducing depression, anxiety, and perceived disability in Parkinson’s disease and are accessible via a Mental Health Treatment Plan (MBS 2715/2717).

D. Australian operations

PBS medicines for Parkinson’s disease

Per PBS (verified 2026-06-04):

• Levodopa/carbidopa, levodopa/benserazide, controlled-release formulations — General
• Pramipexole, ropinirole — General
• Rotigotine transdermal patch — Authority Required
• Apomorphine — Authority Required
• Rasagiline, selegiline, safinamide — General or Authority
• Entacapone, opicapone, levodopa/carbidopa/entacapone — General or Authority
• Amantadine — General
• Rivastigmine for Parkinson’s disease dementia — Authority Required (Streamlined), specialist-initiated
• Quetiapine for Parkinson’s disease psychosis — Authority Required (Streamlined)
• Levodopa-carbidopa intestinal gel (Duodopa) — Section 100 specialist program
• Botulinum toxin for sialorrhoea — Authority Required in selected indications

MBS billing

Standard GP consults (23/36/44); Chronic Disease Management plan 721/723; Team Care Arrangement 723; Home Medicines Review 900 (valuable with complex multi-drug regimens); annual 75+ health assessment 705/707 (embeds Parkinson’s disease review). DAT-SPECT functional brain imaging — MBS 61341/61342 in specialist-requested selected indications. Neurologist 110/116. Mental Health Treatment Plan 2715/2717 for comorbid depression or anxiety.

Driving — Austroads 2022

Per Austroads — Assessing Fitness to Drive 2022, Parkinson’s disease does not automatically preclude driving; mild, stable disease is often compatible with conditional private licensure with regular medical review. Risk increases with cognitive impairment, daytime somnolence (particularly on dopamine agonists — warn explicitly about sleep attacks and driving risk), slowed reaction time, and freezing of gait. An on-road assessment by an occupational therapy driver assessor is often pivotal. Document the discussion at every consultation. Commercial driving is generally not possible.

Hospital admission alert

The “Get It On Time” campaign addresses a critical safety issue: Parkinson’s medications must be given within 30 minutes of the person’s usual scheduled dose. Missed or delayed doses cause freezing, aspiration risk, and an NMS-like syndrome. Provide patients and carers with a medication chart to carry. Avoid metoclopramide, prochlorperazine, and haloperidol in people with Parkinson’s disease; substitute ondansetron for nausea and quetiapine (low dose) for psychosis.

E. Special populations

Older adults (over 75): Falls risk is high and compounds with disease progression. The annual 75+ health assessment (MBS 705/707) should include Parkinson’s disease review with specific attention to postural hypotension, footwear, home safety, and falls prevention physiotherapy. Anticholinergics (benzhexol, benztropine) worsen cognition significantly in older adults and should be avoided except in young tremor-predominant patients.

Young-onset (under 50): Genetic counselling is appropriate; GBA, LRRK2, PRKN, PINK1 variants have therapeutic and family implications. Dopamine agonist monotherapy is often preferred early to reduce lifetime dyskinesia burden. Employment, driving, and relationship implications need proactive discussion from diagnosis.

Residential aged care: “Get It On Time” medication protocols are essential and should be negotiated with facility management. Advance care planning conversations — values, preferred place of care, ceiling of intervention, and swallowing and feeding decisions — should begin by mid-stage disease. Specialist palliative care liaison is appropriate for advanced Parkinson’s disease with dysphagia, recurrent aspiration, and progressive immobility.

When to escalate

Refer to a movement disorder specialist or neurologist when:

• Diagnosis is uncertain (atypical features, rapid progression, early falls, poor levodopa response)
• Treatment initiation or complex adjustment is needed
• Advanced therapies are being considered (DBS, intestinal gel, apomorphine pump)
• DAT-SPECT or genetic testing is planned
• Complex neuropsychiatric features are present (psychosis, dementia, severe treatment-resistant depression)
• Driving fitness formal assessment is needed

Refer to the emergency department or escalate acutely when acute worsening suggests neuroleptic malignancy syndrome (fever, rigidity, confusion), aspiration pneumonia, significant falls injury, or severe medication-related emergency.

What this article is and is not

This is general health information drawn from eTG Neurology, AMH, RACGP clinical guidance, NICE NG71, and major Parkinson’s disease trials including LEAP and EARLYSTIM. It does not constitute personal medical advice and does not create a doctor–patient relationship. Medication choices, dosing, driving fitness assessments, and disease-management decisions are made with your treating GP and neurologist.

For Australian consumer resources: Parkinson’s Australia, HealthDirect — Parkinson’s disease, Better Health Channel.

---

Sources cited

1. RACGP — Parkinson’s care
2. Therapeutic Guidelines (eTG) — Neurology: Parkinson disease
3. Australian Medicines Handbook
4. NICE NG71 — Parkinson’s disease in adults
5. Parkinson’s Australia
6. PBS — Parkinson disease drugs
7. Austroads — Assessing Fitness to Drive 2022
8. HealthDirect — Parkinson’s disease
9. Better Health Channel — Parkinson’s disease
10. Verschuur et al. — LEAP study (NEJM 2019)
11. Postuma et al. — RBD as prodromal Parkinson disease (Brain 2019)
12. Voon et al. — Impulse control disorders in Parkinson disease (Lancet Neurol 2009)
13. Bloem et al. — Parkinson’s disease (Lancet 2021)
14. Movement Disorder Society — MDS Diagnostic Criteria (Postuma 2015)